PCCM Tools

Pulmonary and critical care clinical decision support

IPF longitudinal 6MWT model

Oxygen-Distance-Dyspnea-Saturation (ODDS) Score for Prognosis in IPF

Serial six-minute walk test inputs are translated into ODDS score estimates and predicted event-free survival for adults with idiopathic pulmonary fibrosis.

Six-minute Walk Test Data

0 visits

Enter all available 6MWT results for this patient. Serial data improve longitudinal event-free survival estimation.

Visit Date 6MWD m O2 L/min Rest SpO2 % Nadir SpO2 % Borg

Paste a prior ODDS clinical note table to re-import previous 6MWT rows.

Predicted Event-Free Survival

Add a visit to calculate

1 year --
2 years --
3 years --

Clinical Note Table

Copy formatted ODDS estimates into clinical documentation.

About this tool

Last updated: August 12, 2026

Model Development and Validation

The ODDS score was developed in the ISABELA IPF cohort to use the full signal of the six-minute walk test: oxygen requirement, walk distance, exertional dyspnea, and oxygen saturation, rather than relying on distance alone. It was subsequently externally validated and applied longitudinally, demonstrating that serial ODDS measurements can help estimate evolving event-free survival risk among adult patients with IPF over time.

Evidence and model validation

Contributors

Derivation and validation

Steven D Nathan Jie Gao Ho Cheol Kim Abhimanyu Chandel Henry Chen Xiaomin Lu Bernt van den Blink Lixin Shao Timothy R Watkins Toby M Maher Lisa Lancaster

Longitudinal application and online calculator

Abhimanyu Chandel Stephanie Morgan Junad M. Chowdhury Zein Kattih Vikramjit Khangoora Christopher A. Thomas Christopher S. King Steven D. Nathan

Use and Limitations

This tool is intended to support clinical discussion, risk stratification, and shared decision-making. It is not intended to be used in isolation to determine prognosis or decisions about IPF related management.

This calculator is provided for research and educational purposes only and has not been approved as a medical device. Use does not replace expert clinical assessment.

© 2026 The ODDS Study Authors. All rights reserved unless otherwise noted.

This author-prepared expanded project report is provided to support research evaluation and external validation of ODDS. It has not undergone external peer review and is not a journal version of record.

Citations

  1. Abhimanyu Chandel, Stephanie Morgan, Junad M Chowdhury, Zein Kattih, Vikramjit Khangoora, Christopher A Thomas, Christopher S King, Steven D Nathan. Serial multidomain six-minute walk assessment for dynamic risk prediction in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine. 2026;aamag552. doi:10.1093/ajrccm/aamag552.
  2. Nathan SD, Gao J, Kim HC, Chandel A, Chen H, Lu X, van den Blink B, Shao L, Watkins TR, Maher TM, Lancaster L. Development and validation of a predictive 6-min walk score in patients with idiopathic pulmonary fibrosis. European Respiratory Journal. 2025;66(5):2402565. doi:10.1183/13993003.02565-2024. PMID: 40610052; PMCID: PMC12591136.
  3. Maher TM, Ford P, Brown KK, et al. Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials. JAMA. 2023;329(18):1567-1578. doi:10.1001/jama.2023.5355